Straight Path Wealth Management’s AbbVie ABBV Stock Holding History

Straight Path Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.11M	Sell	4,418 -22	-0.5%	-$4.73K	0.26%	38
2026 Q1	$966K	Buy	4,440 +68	+2%	+$15.1K	0.26%	36
2025 Q4	$999K	Hold	4,372	–	–	0.27%	38
2025 Q3	$1.01M	Buy	+4,372	New	+$890K	0.27%	45

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Straight Path Wealth Management's ABBV Position: Q2 2026 in Review

Straight Path Wealth Management reduced its AbbVie (ABBV) stake by 0.5% in Q2 2026, selling an estimated $4.73K and leaving 4,418 shares worth $1.11M. The position accounts for 0.26% of the portfolio, ranked #38.

Straight Path Wealth Management first reported a position in ABBV in Q3 2025 and has held it in 4 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Straight Path Wealth Management held 4,418 shares of AbbVie worth $1.11M as of Q2 2026.
Straight Path Wealth Management sold 22 AbbVie shares in Q2 2026, an estimated $4.73K.
AbbVie made up 0.26% of Straight Path Wealth Management's portfolio in Q2 2026, its #38 holding.
Straight Path Wealth Management first reported a position in AbbVie in Q3 2025 and has held it in 4 quarters since.
4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Straight Path Wealth Management's 13F filing for Q2 2026, filed 27 Jul 2026.